NKTR August Prediction.

NASDAQ:NKTR   Nektar Therapeutics
NKTR is a bio-pharmaceutical company that has a large pipeline.

July 25th FDA issues letter postponing a Advisory Committee meeting (ADCOM) on their pain relief drug, the postponement is not related to the specific drug itself price drops.
Aug 1st: Breakthrough Therapy Designation given for metastatic melanoma drug
Aug 8th Earnings Report - expect a sell off at ER based on coming week's action. Could be a good time to load up before PDUFA
Aug 29: PDUFA still scheduled.

My Plan:
Basically NKTR got hit with a letter from the FDA knocking it out of it's triangle. Now with good news about the Breakthrough therapy designation it is possibly taking back lost ground. This could be a good chance to get in this company before the Aug 29 PDUFA.

Warning: Biotech stocks have high volatility and are unpredictable which is the nature of the biotech market. Please trade at your own risk. This is just an idea.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.